GlassScriptPhysician profile
Evan Jae Beale
NPI 1689174146
$5,527.58
in general payments reported to CMS, 2019-2025
24 companies · $174 in 2025
The $174 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,168 · 2022: $2,057 · 2023: $809 · 2024: $320 · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,295 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,295.08 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,454.28 | 2021-2024 | |
| Pfizer INC. | $419.40 | 2021-2023 | |
| Janssen Biotech, INC. | $395.03 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $380.74 | 2021-2023 | Dupixent, Libtayo |
| Ucb, INC. | $350.90 | 2021-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $340.51 | 2021-2023 | Ilumya, Absorica Ld, Winlevi |
| Genzyme Corporation | $316.17 | 2021-2022 | |
| Lilly USA, LLC | $255.81 | 2021-2023 | Taltz, Olumiant |
| Incyte Corporation | $229.35 | 2021-2023 | Opzelura |
| Leo Pharma INC. | $205.52 | 2021-2023 | Adbry |
| Almirall LLC | $165.75 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $139.20 | 2021 | |
| Galderma Laboratories, L.P. | $127.08 | 2021-2024 | Epsolay, Oracea, Aklief |
| Janssen Scientific Affairs, LLC | $122.72 | 2021 | |
| Novartis Pharmaceuticals Corporation | $115.80 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $110.61 | 2021-2022 | |
| Biofrontera INC. | $109.27 | 2021-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Stemline Therapeutics INC. | $81.84 | 2021 | |
| Arcutis Biotherapeutics, INC. | $38.99 | 2023 | |
| Vyne Pharmaceuticals INC. | $38.96 | 2021 | |
| Dermavant Sciences, INC. | $37.79 | 2022-2023 | Vtama |
| Tactile Systems Technology INC | $37.55 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $34.95 | 2021 | |
| Dermira, INC. | $19.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Beale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.